Open Text Corporation (OTEX) Stock Price Today
Aura AI Summary
Key Stats
- $6.02BMarket Cap
- -Volume
- TechnologySector
- $39.6952W High
- $20.0152W Low
- -Typical Hold Time
- $11.03BEnterprise Value
- 4.5%Div Yield
- -Trading Activity
Track Open Text Corporation (OTEX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Open Text Corporation has traded between a low of $20.01 and a high of $39.69, highlighting its annual price range. Buy and sell Open Text Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Most Recent News
Major stocks fall sharply amid mixed earnings and negative outlooks, signaling broader market concerns.
Several leading stocks, including SoundThinking, TSS, and ADI Global Distribution, dropped significantly due to factors like lowered revenue forecasts and disappointing quarterly results. SoundThinking fell over 25% after cutting its revenue outlook ...

Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.